All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 22 February 2018, Sarah Huet from the Cancer Research Center of Lyon and Bruno Tesson from the Carnot Institute CALYM, France, and colleagues, published online ahead of print, in The Lancet Oncology, a multicenter international validation analysis for a predictive gene-expression model of follicular lymphoma (FL).
Because of the heterogeneity in clinical outcomes for FL patients, there is a strong need for a predictive model that will facilitate distinctive diagnosis between high- and low-risk disease progression or transformation patients. Despite Follicular Lymphoma International Prognostic Index (FLIPI-1 and FLIPI-2) scores being good pre-treatment clinical outcome predictors, they do not provide realistic long-term profiling for FL patients. Thus, this study sought to build and validate, from gene-expression data on tumor biology and microenvironment, a predictive model for FL patients of all risk types.
The authors designed their FL-predictive model by retrospectively analyzing pre-treatment tumor biopsies from grade 1–3a FL patients participating in PRIMA, a phase III clinical trial (NCT00140582), investigating rituximab maintenance in high-grade FL (training cohort). The model was further validated in pre-treatment biopsies obtained from three independent international ‘validation cohorts’ from the: (a) SPORE project, University of Iowa, Mayo Clinic, (b) Hospital Clinic of Barcelona, and (c) a separate population from PRIMA.
This study developed and validated a 23-gene expression model that predicts clinical outcomes and PFS in high- and low-risk FL patients. Advantages of the model include its application to routinely available formalin-fixed, paraffin-embedded specimens and that it takes into consideration tumor biology and microenvironment heterogeneity. According to the authors, the model accurately identified high-risk FL patients independently of FLIPI score or rituximab maintenance therapy. They state that together with the FLIPI index, this model presents a useful tool for enabling individualized risk group-directed therapy for FL patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox